research Advances in the Management of Cutaneous Toxicities of Targeted Therapies
Targeted cancer therapies often cause skin problems that need careful management to improve patient quality of life and treatment success.
Search
for
Sort by
Research
570-600 / 1000+ results research Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea
Lenvatinib and sorafenib are generally safe but need dose adjustments due to side effects.
research Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda®)
Capecitabine is as effective as intravenous treatments with fewer side effects, but requires careful management of Hand-foot syndrome and patient education.
research Cutaneous Drug Eruptions Associated with the Use of New Oncological Drugs
New cancer drugs often cause skin and nail problems.
research Non-Rash Skin Toxicities Associated with Novel Targeted Therapies
Early recognition and management of skin side effects from new cancer therapies can prevent treatment delays.
research Innovative Uses for Zinc in Dermatology
Zinc can be a helpful secondary treatment for certain skin conditions, but more research is needed to guide its use.
research Finasteride adverse effects in subjects with androgenic alopecia: A possible therapeutic approach according to the lateralization process of the brain
Finasteride may cause mental and sexual side effects, with hand preference and sexual orientation possibly affecting severity.
research Dermoscopic evaluation of skin in healthy cats
Dermoscopy is a good, noninvasive way to see normal cat skin structures and could be useful for check-ups.
research Chemotherapy-induced iatrogenic injury of skin: New drugs and new concepts
New chemotherapy drugs cause skin side effects, but treatments like minocycline and tetracycline can help reduce them.
research Skin toxicity of anti‐cancer therapy
Anti-cancer treatments can cause reversible hair loss, skin sensitivity, pigmentation changes, nail damage, and skin reactions, with a need for more research on managing these side effects.
research The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors
EGFR inhibitors can cause various skin issues during cancer treatment, and managing these is important for patient care.
research Cutaneous reactions to targeted therapies in children with CNS tumors: A cross‐sectional study
Most children with CNS tumors on targeted therapy had skin reactions, which were generally treatable without stopping the therapy.
research Sorafenib combined with hepatectomy in patients with intermediate-stage and advanced hepatocellular carcinoma
Sorafenib after liver surgery may increase survival for some liver cancer patients.
research Prophylaxis and Management of Skin Toxicities
Preventive measures and effective management are crucial for reducing skin side effects in cancer treatment.
research Clinical Management of Cutaneous Adverse Events in Patients on Chemotherapy: A National Consensus Statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
Proper skin toxicity management in chemotherapy is key to continuing treatment and keeping patient quality of life high.
research Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib
Deferasirox combined with sorafenib reduces liver cancer risk and lessens treatment side effects.
research Patient‐Level Adverse Event Patterns in a Single‐Institution Study of the Multi‐Kinase Inhibitor Sorafenib
Sorafenib often causes mucositis, hand-foot syndrome, rash, alopecia, diarrhea, and fatigue.
research Impact of the COVID‐19 pandemic on inpatient dermatology: a multicentre study from Hubei, China
COVID-19 led to fewer dermatology admissions in Hubei, China, with more severe cases and increased eczema due to mask use and hand disinfectants.
research Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment
New targeted cancer drugs can cause skin side effects, and managing them requires patient education and timely care.
research The O'Connor Tweezer Dexterity Test as a Screening Tool for Hiring Surgical Hair Restoration Assistants
The O'Connor Tweezer Dexterity Test effectively screens for skilled surgical hair restoration assistants.
research Targeted Therapy– and Chemotherapy-Associated Skin Toxicities: Systematic Review and Meta-Analysis
Minocycline reduces acne rash, pyridoxine lowers hand-foot syndrome risk, and scalp cooling lessens hair loss from cancer treatments.
research Norman Orentreich, The Father of Hair Transplantation
Norman Orentreich pioneered hair transplantation, improving techniques over time for more natural results.
research Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
Cancer treatments often cause skin, nail, and hair problems.
research Footprints of the EADV: a meeting report from the 17th Congress of the European Academy of Dermatology and Venereology
The conference highlighted new dermatological treatments and emphasized early intervention and addressing conditions lacking evidence-based treatments.
research Diagnosis and treatments of hirsutism: where are we?
Effective treatments for excessive hair growth in women include creams, laser therapy, and medications, with the choice depending on individual needs and potential side effects.
research Cutaneous Adverse Events of Targeted Anticancer Therapy: A Review of Common Clinical Manifestations and Management
Targeted anticancer therapies often cause skin issues, affecting treatment adherence and quality of life.
research Topoisomerase‐Interacting Agents
Topoisomerase inhibitors can cause hair loss, skin rash, hand-foot syndrome, and nail changes.
research Large-Scale, Multicenter, Prospective Registry Study of Ripretinib in Advanced GIST: A Real-World Study from China
Ripretinib is effective and safe for treating advanced GIST in Chinese patients, particularly for non-gastric GISTs.
research Reply to letter to the editor: “A response to ‘Male balding is a major risk factor for severe COVID-19’”
Balding might help identify men at higher risk for severe COVID-19, but more research is needed.
research Updates from the British Association of Dermatologists 91st Annual Meeting, 5-7 July 2011, London, U.K.
New treatments and management strategies for skin conditions like melanoma and Spitz naevi were discussed at the dermatologists' meeting.